Mydecine Innovations Group Inc. (FRA:0NF0)
Germany · Delayed Price · Currency is EUR 0.1500
0.00 (0.00%)
Last updated: Nov 21, 2025, 8:00 AM CET
Mydecine Innovations Group Company Description
Mydecine Innovations Group Inc., a biotechnology company, engages in the research, development, and commercialization of psilocybin products to treat mental health conditions.
The company primarily focuses on treating nicotine addiction and post-traumatic stress disorder. It also develops MYCO-005, MYCO-006, and MYCO-007 for MDMA and psilocybin analogs.
The company has a partnership with Applied Pharmaceutical Innovation for pharmaceutical drug discovery, research, and development on empathogenic and entactogenic compounds.
Mydecine Innovations Group Inc. was formerly known as NewLeaf Brands Inc. and changed its name to Mydecine Innovations Group Inc. in June 2020.
The company was incorporated in 2013 and is headquartered in Vancouver, Canada.
Mydecine Innovations Group Inc.
| Country | Canada |
| Founded | 2013 |
| Industry | Agricultural Production Crops |
| CEO | David Bartch |
Contact Details
Address: 1075 West Georgia Street Vancouver, British Columbia V6E 3C9 Canada | |
| Phone | 604 687 2038 |
| Website | mydecine.com |
Stock Details
| Ticker Symbol | 0NF0 |
| Exchange | Frankfurt Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CAD |
| SIC Code | 0100 |
Key Executives
| Name | Position |
|---|---|
| David Bartch | Chief Executive Officer |
| John Ross | Chief Financial Officer |